Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Vanda Pharmaceuticals
Biotech
Vanda Pharmaceuticals shares in the red as phase 3 flops
Vanda Pharmaceuticals is hoping to try again with an amended trial after its experimental skin drug tradipitant failed a phase 3 test.
Ben Adams
Feb 26, 2020 7:50am
FDA wins legal dispute with Vanda over partial clinical hold
Feb 4, 2020 8:30am
FDA snubs jet lag filing for Hetlioz, 'perplexing' Vanda
Aug 19, 2019 10:20am
Vanda's atopic dermatitis drug misses mark in ph2 trial
Sep 14, 2017 6:09am
Biotech IPOs; CHMP knockbacks—News of Note
Jul 21, 2017 8:25am
